Cointime update: China’s National Healthcare Security Administration on Nov. 14 published its updated list of drugs newly covered by the national medical insurance catalogue and the commercial insurance innovative drug catalogue, adding Jinbeixin (fuxinizumab), a Class 1 innovative biologic developed by GeneSci Pharmaceutical. The drug is dosed once every six months.
China’s National Medical Insurance Scheme Adds GeneSci’s Gout Drug Jinbeixin
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
1h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
1h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips
2h ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%
2h ago
Goldman Sachs Forecasts Gold May Return to $5,600 by Late 2028
3h ago
Dollar Holds Near 19-Month High on Fed Rate Hike Expectations